Literature DB >> 2147576

Success of a program of routine prenatal screening for hepatitis B surface antigen: the first 2 years.

N B Okun1, R P Larke, J R Waters, M R Joffres.   

Abstract

Prenatal screening for hepatitis B surface antigen (HBsAg) restricted to women with defined risk factors for chronic hepatitis B virus (HBV) infection fails to identify many carriers. A centralized program of routine HBsAg screening for all pregnant women in Alberta was introduced in 1985. We collected and analysed data for the first 2 years of the program in Edmonton to determine the frequency of risk factors for HBsAg positivity, the proportion of multiparous HBsAg-positive women not identified in previous pregnancies, the efficiency and cost-effectiveness of providing immunoprophylaxis to infants at risk of HBV infection and the degree of success in inducing adequate protection. A total of 149 women (158 pregnancies) were found to be HBsAg positive. Risk factors were readily ascertainable for 85% of the women; the remaining 15% would not have been identified through risk-selective screening. The most common risk factors were Oriental ethnic origin, history of hepatitis, jaundice or multiple transfusions of blood or blood products, and occupational exposure to blood. Although 86% of the multiparous HBsAg-positive women had risk factors, only 7% had been identified in previous pregnancies. The Alberta program appears to be cost-effective. We conclude that only routine prenatal screening will identify all infants at risk of perinatal HBV infection and that a comprehensive public health program involving central laboratories, private physicians and public health staff can be highly effective and efficient in protecting infants against hepatitis B.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2147576      PMCID: PMC1452934     

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


  13 in total

1.  Solid-phase enzyme immunoassay for hepatitis B surface antigen.

Authors:  R Wei; G J Knight; D H Zimmerman; H E Bond
Journal:  Clin Chem       Date:  1977-05       Impact factor: 8.327

2.  The pregnant hepatitis B carrier: evidence favoring comprehensive antepartum screening.

Authors:  P R Summers; M K Biswas; J G Pastorek; M L Pernoll; L G Smith; B E Bean
Journal:  Obstet Gynecol       Date:  1987-05       Impact factor: 7.661

3.  Cost-effectiveness of prenatal screening and immunization for hepatitis B virus.

Authors:  J A Arevalo; A E Washington
Journal:  JAMA       Date:  1988-01-15       Impact factor: 56.272

4.  Prevention of chronic hepatitis B virus infection from mothers to infants in the United States.

Authors:  J Chin
Journal:  Pediatrics       Date:  1983-02       Impact factor: 7.124

5.  Hepatitis B infection in a large municipal obstetrical population: characterization and prevention of perinatal transmission.

Authors:  M M Jonas; R K Reddy; M DeMedina; E R Schiff
Journal:  Am J Gastroenterol       Date:  1990-03       Impact factor: 10.864

6.  Prevention of perinatal transmission of hepatitis B virus: the sensitivity, specificity, and predictive value of the recommended screening questions to detect high-risk women in an obstetric population.

Authors:  G M McQuillan; T R Townsend; C B Johannes; T Dillard; R A Molteni; P M Ness; J R Niebyl
Journal:  Am J Epidemiol       Date:  1987-09       Impact factor: 4.897

7.  Should all pregnant women be screened for hepatitis B?

Authors:  M L Kumar; N V Dawson; A J McCullough; M Radivoyevitch; K C King; R Hertz; H Kiefer; M Hampson; R Cassidy; A S Tavill
Journal:  Ann Intern Med       Date:  1987-09       Impact factor: 25.391

8.  Hepatitis B: a controllable disease.

Authors:  D A Baker; B F Polk
Journal:  Obstet Gynecol       Date:  1983-07       Impact factor: 7.661

9.  Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B immune globulin and hepatitis B vaccine.

Authors:  R P Beasley; L Y Hwang; G C Lee; C C Lan; C H Roan; F Y Huang; C L Chen
Journal:  Lancet       Date:  1983-11-12       Impact factor: 79.321

10.  Prevalence of hepatitis B virus infection in pregnant women in the Montreal area.

Authors:  G Delage; S Montplaisir; S Rémy-Prince; E Pierri
Journal:  CMAJ       Date:  1986-04-15       Impact factor: 8.262

View more
  7 in total

1.  Overcoming barriers to hepatitis B immunisation by a dedicated hepatitis B immunisation service.

Authors:  V F Larcher; J Bourne; C Aitken; D Jeffries; D Hodes
Journal:  Arch Dis Child       Date:  2001-02       Impact factor: 3.791

2.  Prevention of perinatal hepatitis B virus transmission in an obstetric/infant population.

Authors:  P J Parker; T W Gyorkos; J S Dylewski; A K Joshi; E D Franco
Journal:  Can J Infect Dis       Date:  1993-09

3.  Antenatal screening for carriers of hepatitis B virus.

Authors:  E H Boxall
Journal:  BMJ       Date:  1995-11-04

4.  Hepatitis B Infection in Canada: Epidemiology and implications for control.

Authors:  G Delage; A O Carter
Journal:  Can Fam Physician       Date:  1992-11       Impact factor: 3.275

5.  Prenatal screening for hepatitis B surface antigen. Is universal screening necessary?

Authors:  B A Morris; L Sabetti
Journal:  Can Fam Physician       Date:  1993-01       Impact factor: 3.275

6.  Outcomes from a Canadian public health prenatal screening program for hepatitis B: 1997-2004.

Authors:  Sabrina S Plitt; Ali M Somily; Ameeta E Singh
Journal:  Can J Public Health       Date:  2007 May-Jun

7.  Enhanced surveillance for childhood hepatitis B virus infection in Canada, 1999-2003.

Authors:  H X Wu; A Andonov; A Giulivi; N J Goedhuis; B Baptiste; J Furseth; D Poliquin; J I P Chan; G Bolesnikov; B Moffat; S Paton; J Wu
Journal:  Int J Med Sci       Date:  2005-10-01       Impact factor: 3.738

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.